BTG SP Makes A Virtue Of Manufacturing And Supply Discipline Despite COVID
Risk Minimization Strategy Paid Off For BTG Specialty Pharma, Which Recently Became Part Of The SERB Group
Executive Summary
Manufacturing and supply chain resilience ensured that BTG Specialty Pharma met its sales target in the COVID-affected 2020. Its president, Anthony Higham, explained how this was possible while the company busily ̶ and quietly – sought new ownership, and all under the shadow of Brexit.
You may also be interested in...
SERB And BTG SP – A Simple Jigsaw
The merging of the capabilities of Belgium’s SERB and the UK’s BTG Specialty Pharma could produce the world’s biggest antidotes manufacturer.
SERB And BTG SP – A Simple Jigsaw
The merging of the capabilities of Belgium’s SERB and the UK’s BTG Specialty Pharma could produce the world’s biggest antidotes manufacturer.
Boston Scientific's Drive To Add To Core Strength Continues With BTG Buy
When Boston Scientific chief medical officer Ian Meredith spoke in mid-2018 of the group's appetite for core M&A, there was a sense that more strategic moves were likely before the year was out. The inference was right, and a busy year for Boston Scientific got much busier when it made a cash offer for UK interventional medicine specialist BTG PLC. The bid values the target company at $4.28 billion, and completion is expected by mid-2019.